Urine test detects bladder cancer and guides treatment choice
Stanford Medicine and VA Palo Alto researchers developed a urine test that detects bladder cancer with 95% accuracy, outperforming standard methods, and predicts whether patients will respond better to immunotherapy or chemotherapy. The test, called uRARE-seq, analyzes RNA messages shed by tumor cells into urine rather than DNA mutations, capturing tumor behavior. In 683 samples, it correctly identified 95% of localized bladder cancer cases and 90% of healthy individuals, surpassing urine cytology and DNA-based tests. Bladder cancer affects about 85,000 Americans annually and is monitored via invasive cystoscopy, which misses up to 30% of cases. The test could guide BCG immunotherapy decisions, which currently lack predictive biomarkers, and help ration scarce BCG supplies. Researchers plan larger prospective trials to validate the approach.